Drug Trial Radar · NCT05890781
Engineering Immune Organoids to Study Pediatric Cancer
Last checked: Nov 19, 2026Latest source record: Feb 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
108
Planned (sponsor's estimate)
Start
May 12, 2023
Primary completion
May 2028
Study completion May 2028
Sponsor
- Lead sponsor
- Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 6, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, up to 25 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)
Conditions
- Brain Tumor
- Kidney Tumor
- Neuroblastoma
- Sarcoma
Interventions
Skin biopsyProcedure
Skin biopsy
Fresh tumor sampleProcedure
Fresh tumor sample
Blood sampleBiological
Blood sample in heparin tubes (highly recommended), to be collected before starting treatment or as soon as hematological recovery has been reached
Healthy tissue from the tumorProcedure
Healthy tissue from the tumor site whenever possible
Spinal cerebrospinal fluid (SCF)Procedure
Spinal cerebrospinal fluid (SCF) whenever possible
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of viable and exploitable immune organoids with engrafted tumor cellsTime frame: until 5 years after enrolment
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Gustave Roussy
Villejuif, France · Recruiting
Hopital Necker
Paris, Île-de-France Region, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.